Predicting risks and outcomes for lung disease in myositis patients
Myositis-ILD Risk Prediction Models and Endotypes
This study is looking to help people with interstitial lung disease linked to myositis by finding better ways to predict how their condition will progress, using information from different patients and their genes, so that doctors can provide the right level of care for everyone, no matter where they live.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10883025 on NIH RePORTER |
What this research studies
This research focuses on improving the prediction of long-term outcomes for patients suffering from interstitial lung disease (ILD) associated with myositis. By analyzing a diverse group of patients, the study aims to develop better models that can accurately forecast disease progression using both clinical data and genetic markers. The researchers will refine existing models and validate them across different populations, particularly outside of Asia, to ensure they are applicable to a broader range of patients. This approach seeks to address the current inadequacies in treatment strategies that often lead to either insufficient or overly aggressive care.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with myositis who are also experiencing interstitial lung disease.
Not a fit: Patients with myositis who do not have interstitial lung disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate prognostic tools that help tailor treatments for myositis-ILD patients, improving their overall care and outcomes.
How similar studies have performed: Previous research has indicated that specific genetic markers can influence disease susceptibility and progression, suggesting that this approach has potential for success.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Johnson, Cheilonda — University of Pennsylvania
- Study coordinator: Johnson, Cheilonda
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.